Long-term outcomes with HLX01 (HanliKang®), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study
Article in BMC Cancer (January 2024)
The most recent citing publications are shown below. View all 22 publications that cite this research output on Dimensions.
Article in BMC Cancer (January 2024)
Article in JAMA Network Open (October 2023)
Article in Frontiers in Immunology (April 2023)